Ulcerative Colitis

Led by Mount Sinai, Trellus Health Nabs $5M for Precision Platform for Complex Chronic Conditions

  • by

What You Should Know: – Trellus Health secures $5M in seed funding and collaborates with Mount Sinai to deliver resilience-driven, connected care, integrating expert clinical and behavioral health for better outcomes. – The first disease Trellus will tackle is IBD, which is one of the… Read More »Led by Mount Sinai, Trellus Health Nabs $5M for Precision Platform for Complex Chronic Conditions

FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

  • by

Roche Set to Compete With Biogen and Novartis in the SMA Market With its First Oral Therapy  The US FDA has recommended the use of Evrysdi (risdiplam), a candidate of Genentech, a Roche company, for spinal muscular atrophy (SMA), an inherited neuromuscular disease resulting in… Read More »FDA’s Ok to Roche’s Oral SMA Therapy; Roche’s Etrolizumab Mixed Results in Ulcerative Colitis; Secura receives rights to Copiktra from Verastem

Roche’s ulcerative colitis drug etrolizumab looks shaky after data roll-out

  • by

Roche’s late-stage trial programme for ulcerative colitis candidate etrolizumab has generated some positive and negative results, but leans firmly towards the latter. The Swiss drugmaker has acknowledged that the dual-acting anti-integrin antibody – which is trying to chase down Takeda’s blockbuster Entyvio in UC –… Read More »Roche’s ulcerative colitis drug etrolizumab looks shaky after data roll-out

Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis

  • by

Shots: In the HIBISCUS I induction study, in patients without prior anti-TNF treatment, etrolizumab met its 1EPs while in HIBISCUS II study in the same kind of people, it did not meet its 1EPs. In the HICKORY study, in patients with prior anti-TNF treatment, therapy… Read More »Roche Report Mixed Results of Etrolizumab in P-III Studies for Patients with Moderately to Severely Active Ulcerative Colitis